Protocol
09-131
Full Title
A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Purpose
Carboplatin and paclitaxel are standard drugs for the treatment of head and neck cancer. Temsirolimus is approved for the treatment of advanced kidney cancer and is considered investigational for head and neck cancer.
Temsirolimus blocks a molecule called mTOR, which appears to function abnormally in head and neck cancer. In laboratory studies, temsirolimus improved the ability of carboplatin and paclitaxel to kill head and neck cancer cells.
At Memorial Sloan-Kettering, investigators will be conducting the phase I portion of this study to find the optimal dose of temsirolimus to give with carboplatin and paclitaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of squamous cell carcinoma of the head and neck.
- At least 6 weeks must have passed since completion of prior radiation therapy and entry into the study, and patients must have recovered from any side effects.
- Patients may not have had more than two prior regimens of chemotherapy.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Matthew G. Fury at 646-888-4233.
Disease(s)
Head & Neck Cancer
Locations
ClinicalTrials.gov
Related Diseases
